High doses of Levothyroxine increase atrial fibrillation risk in elderly, finds study
Canada: The administration of levothyroxine at a dose above 0.075 mg/day in older adults may increase the risk of atrial fibrillation (AF) compared to exposure to a lower dose, suggests a recent study in the American Heart Journal.
Due to the lack of data pertaining to the effect of levothyroxine dose on the occurrence of AF are lacking, particularly in the older population, Inna Y.Gong, Department of Medicine, University of Toronto, Canada, and colleagues determine the effect of cumulative levothyroxine exposure on AF and ischemic stroke risk in older adults.
For the purpose, the researchers conducted a population-based observational study using healthcare databases from Ontario, Canada. 189,672 older adults aged ≥66 years (mean age 82 years; 72% women) without a history of AF who filled at least one levothyroxine prescription between April 1st, 2007, and March 31st, 2016 were included.
Cases were defined as cohort members who had incident AF (emergency room visit or hospitalization) between the date of first levothyroxine prescription and December 31st, 2017. Cases were matched with up to five controls without AF on the same index date. The index date was the date of AF
The secondary outcome was ischemic stroke. Cumulative levothyroxine exposure was estimated based on total milligrams (mg) of levothyroxine dispensed in the year prior to the index date.
Key findings of the study include:
- 16.1% had an episode of AF.
- Compared to low levothyroxine exposure, high and medium exposure was associated with significantly increased risk of AF after adjustment for covariates (adjusted odds ratio, aOR 1.29, aOR 1.08 respectively).
- No association was observed between levothyroxine exposure and ischemic stroke.
- Compared with current levothyroxine use, older adults with remote levothyroxine use had lower risks of AF (aOR 0.56) and ischemic stroke (aOR 0.61).
"Among older persons treated with levothyroxine, levothyroxine at doses above 0.075 mg/day is associated with an increased risk of AF compared to lower exposure," concluded the authors.
"Levothyroxine dose and risk of atrial fibrillation: a nested case-control study," is published in the American Heart Journal.
DOI: https://www.sciencedirect.com/science/article/abs/pii/S0002870320302726
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.